Aroda VR, Bain SC, Cariou B et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Trials show up to 17% body weight loss
But writing prescriptions while skimping on care is not in the Hippocratic oath. McClain says she overdosed on an injectable weight loss medication in January after following dosing instructions from a telehealth provider
2022;45(Suppl 1):S125-s43
You cannot pick your dose, and you need to live close enough to a trial site to attend in person
Rated 5 out of 5 Maritza (verified owner) Tirzepatide works wonderfully